scholarly journals Predicting hypertensive disorders in pregnancy using multiple methods: Models with the placental growth factor parameter

2021 ◽  
Vol 29 ◽  
pp. 427-432
Author(s):  
Ge Sun ◽  
Qi Xu ◽  
Song Zhang ◽  
Lin Yang ◽  
Guoli Liu ◽  
...  
Keyword(s):  
Growth Factor ◽  
Placental Growth Factor ◽  
Final Model ◽  
Hypertensive Disorders ◽  
Hypertensive Disorders In Pregnancy ◽  
Comprehensive Comparison ◽  
Lasso Method ◽  
In Pregnancy ◽  
Better Than ◽  
Predictive Effect

BACKGROUND: Placental growth factor (PlGF), one of the biomarkers, has a certain predictive effect on hypertensive disorders in pregnancy (HDP). OBJECTIVE: To study the HDP prediction effect of different methods for variable selection and modeling for models containing PlGF. METHODS: For the model containing PlGF, the appropriate range of PlGF parameters needed to be selected. Step-logistic regression and lasso were used to compare the model effect of twice range selection. The PlGF model with good predictive effect and appropriate detecting gestational age was selected for the final prediction. RESULTS: The effect of the model containing PlGF tested at 15–16 weeks was better than the PlGF value without comprehensive screening. The sensitivity of both methods was over 92%. By comprehensive comparison, the final model of lasso method in this study was more effective. CONCLUSIONS: In this study, a variety of methods were used to screen models containing PlGF parameters. According to clinical needs and model effects, the optimal HDP prediction model with PlGF parameters in the second trimester of 15–26 weeks of pregnancy was finally selected.

scholarly journals Prediction of hypertensive disorders in pregnancy based on placental growth factor

2021 ◽  
Vol 29 ◽  
pp. 165-170
Author(s):  
Qi Xu ◽  
Ge Sun ◽  
Song Zhang ◽  
Guoli Liu ◽  
Lin Yang ◽  
...  
Keyword(s):  
Growth Factor ◽  
Predictive Performance ◽  
Placental Growth Factor ◽  
Model Accuracy ◽  
Model Quality ◽  
Maternal Characteristics ◽  
Hypertensive Disorders ◽  
Hypertensive Disorders In Pregnancy ◽  
Comprehensive Comparison ◽  
In Pregnancy

BACKGROUND: The prediction of hypertensive disorders in pregnancy (HDP) mainly involves various aspects such as maternal characteristics and biomarkers. OBJECTIVE: We aimed to study the effect of the HDP prediction model with or without placental growth factor (PlGF). METHODS: This study used maternal factors and PlGF, and standardized the data uniformly. At 12–20 weeks, the comprehensive comparison of model quality with or without PlGF was conducted by logistic regression. RESULTS: The area under curve and the model accuracy of the model with PlGF were higher than those of the model without PlGF. The accuracy of the model with PlGF was above 90%. CONCLUSIONS: Adding PlGF to the model for predicting HDP improved the accuracy and effectiveness of the model. This study confirmed the predictive performance of PlGF.

P22. Evaluation of a new, simple and rapid placental growth factor test for the evaluation of hypertensive disorders in pregnancy

2011 ◽  
Vol 1 (3-4) ◽  
pp. 283 ◽  
Author(s):  
Balázs Stenczer ◽  
Attila Molvarec ◽  
Nóra Gullai ◽  
Gergely Fügedi ◽  
Bálint Nagy ◽  
...  
Keyword(s):  
Growth Factor ◽  
Placental Growth Factor ◽  
Hypertensive Disorders ◽  
Hypertensive Disorders In Pregnancy ◽  
In Pregnancy

scholarly journals Urinary placental growth factor as a predictor of complications in hypertensive disorders in pregnancy: a protocol for systematic review and meta-analysis

BMJ Open ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. e046005
Author(s):  
Camille Francoeur ◽  
Julie Moreau ◽  
Samuel Lemaire-Paquette ◽  
Marie-Claude Battista ◽  
Marie-Eve Roy-Lacroix ◽  
...  
Keyword(s):  
Systematic Review ◽  
Growth Factor ◽  
Pregnant Women ◽  
Meta Analysis ◽  
Placental Growth Factor ◽  
Study Quality ◽  
Hypertensive Disorders ◽  
Hypertensive Disorders In Pregnancy ◽  
Study Quality Assessment ◽  
In Pregnancy

IntroductionPreeclampsia is an important cause of maternal and fetal morbidity and mortality. Although the diagnostic and prognostic values of circulating placental growth factor (PlGF) have been extensively studied, urinary PlGF represents an excellent alternative to facilitate sample collection in the follow-up of pregnant women. The aim of this study is to determine whether urinary PlGF levels throughout pregnancy can predict severe maternal, fetal/placental and neonatal complications in women with hypertensive disorders in pregnancy.Methods and analysisStudies that evaluated pregnant women with hypertensive disorders and at least one measurement of urinary PlGF will be included. Studies that measure urinary PlGF after the occurrence of the complications will be excluded. The main outcome will consist of severe maternal complications in women with hypertensive disorders in pregnancy. Secondary outcomes will consist of severe fetal/placental and neonatal complications as defined by the International Collaboration to Harmonize Outcomes for Pre-eclampsia. Prospective cohort studies and case–controls studies reporting original data will be included. Studies will be identified by searching MEDLINE and SCOPUS databases. The first literature search was conducted on 2 March 2020, and another search will be performed before analyses. All eligible studies will be assessed for risk of bias with a standardised 10-items study quality assessment tool adapted from the Study Quality Assessment tools developed by the National Institutes of Health (NIH). Summary of ORs and 95% CIs will be reported to evaluate the association between urinary PlGF levels and hypertensive disorders in pregnancy and its complications. A random-effect meta-analysis will also be performed.Ethics and disseminationReview by an ethics committee will not be required for this systematic review. This study will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and will be submitted for publication in a peer-reviewed journal as well as for presentation at conferences targeting different stakeholders, including researchers, physicians and patients.PROSPERO registration numberCRD42020186313.

BASIC FIBROBLAST GROWTH FACTOR AND HYPERTENSIVE DISORDERS IN PREGNANCY

2002 ◽  
Vol 21 (3) ◽  
pp. 235-241 ◽  
Author(s):  
Maria Hohlagschwandtner ◽  
Martin Knöfler ◽  
Meinhard Ploner ◽  
Harald Zeisler ◽  
Elmar A. Joura ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Basic Fibroblast Growth Factor ◽  
Fibroblast Growth ◽  
Hypertensive Disorders ◽  
Hypertensive Disorders In Pregnancy ◽  
In Pregnancy

Prevalence and Risk Factors of Hypertensive Disorders in Pregnancy: Case of Mezam Division, NWR Cameroon

2020 ◽  
Vol 03 (03) ◽  
Author(s):  
Nkem Ernest Njukang ◽  
Tah Aldof Yoah ◽  
Martin Sama ◽  
Thomas Obinchemti EGBE ◽  
Joseph Kamgno
Keyword(s):  
Risk Factors ◽  
Hypertensive Disorders ◽  
Hypertensive Disorders In Pregnancy ◽  
In Pregnancy

scholarly journals Prevalence and determinants of chronic kidney disease in women with hypertensive disorders in pregnancy in Nigeria: a cohort study

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Salisu M. Ishaku ◽  
Timothy Olusegun Olanrewaju ◽  
Joyce L. Browne ◽  
Kerstin Klipstein-Grobusch ◽  
Gbenga A. Kayode ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Gestational Hypertension ◽  
Monitoring Program ◽  
Sub Saharan Africa ◽  
Future Research ◽  
Hypertensive Disorders ◽  
Hypertensive Disorders In Pregnancy ◽  
Sub Saharan ◽  
In Pregnancy

Abstract Background Worldwide, hypertensive disorders in pregnancy (HDPs) complicate between 5 and 10% of pregnancies. Sub-Saharan Africa (SSA) is disproportionately affected by a high burden of HDPs and chronic kidney disease (CKD). Despite mounting evidence associating HDPs with the development of CKD, data from SSA are scarce. Methods Women with HDPs (n = 410) and normotensive women (n = 78) were recruited at delivery and prospectively followed-up at 9 weeks, 6 months and 1 year postpartum. Serum creatinine was measured at all time points and the estimated glomerular filtration rates (eGFR) using CKD-Epidemiology equation determined. CKD was defined as decreased eGFR< 60 mL/min/1.73m2 lasting for ≥ 3 months. Prevalence of CKD at 6 months and 1 year after delivery was estimated. Logistic regression analyses were conducted to evaluate risk factors for CKD at 6 months and 1 year postpartum. Results Within 24 h of delivery, 9 weeks, and 6 months postpartum, women with HDPs were more likely to have a decreased eGFR compared to normotensive women (12, 5.7, 4.3% versus 0, 2 and 2.4%, respectively). The prevalence of CKD in HDPs at 6 months and 1 year postpartum was 6.1 and 7.6%, respectively, as opposed to zero prevalence in the normotensive women for the corresponding periods. Proportions of decreased eGFR varied with HDP sub-types and intervening postpartum time since delivery, with pre-eclampsia/eclampsia showing higher prevalence than chronic and gestational hypertension. Only maternal age was independently shown to be a risk factor for decreased eGFR at 6 months postpartum (aOR = 1.18/year; 95%CI 1.04–1.34). Conclusion Prior HDP was associated with risk of future CKD, with prior HDPs being more likely to experience evidence of CKD over periods of postpartum follow-up. Routine screening of women following HDP-complicated pregnancies should be part of a postpartum monitoring program to identify women at higher risk. Future research should report on both the eGFR and total urinary albumin excretion to enable detection of women at risk of future deterioration of renal function.

Sign in / Sign up

Export Citation Format

Share Document